Reports the influence of BRCA status on tumor response to paclitaxel in ovarian cancer, suggesting potential treatment adjustments.
What is already known on this topic Platinum resistant ovarian cancer has a poor prognosis with limited therapeutic options. Efforts should focus on identifying predictive biomarkers.What this study adds BRCA status may influence tumor sensitivity to paclitaxel in platinum resistant ovarian cancer, with greater efficacy observed in BRCAwt compared to BRCAmut patients.How this study might affect research, practice or policy BRCA status could guide therapeutic choices, favoring alternative regimens or combinations with immune checkpoint inhibitors or antiangiogenetic agents to improve the treatment of ovarian cancer in the platinum resistant setting.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: